NAV

Clostebol

Identification

Name
Clostebol
Accession Number
DB01521
Description
Not Available
Type
Small Molecule
Groups
Experimental, Illicit
Structure
Thumb
3D
Similar Structures
Weight
Average: 322.869
Monoisotopic: 322.169957815
Chemical Formula
C19H27ClO2
Synonyms
Not Available

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Unlock Additional Data
Beclomethasone dipropionateThe risk or severity of edema formation can be increased when Clostebol is combined with Beclomethasone dipropionate.
BetamethasoneThe risk or severity of edema formation can be increased when Clostebol is combined with Betamethasone.
Betamethasone phosphateThe risk or severity of edema formation can be increased when Clostebol is combined with Betamethasone phosphate.
BudesonideThe risk or severity of edema formation can be increased when Clostebol is combined with Budesonide.
CiclesonideThe risk or severity of edema formation can be increased when Clostebol is combined with Ciclesonide.
ClobetasolThe risk or severity of edema formation can be increased when Clostebol is combined with Clobetasol.
Clobetasol propionateThe risk or severity of edema formation can be increased when Clostebol is combined with Clobetasol propionate.
CorticotropinThe risk or severity of edema formation can be increased when Clostebol is combined with Corticotropin.
Cortisone acetateThe risk or severity of edema formation can be increased when Clostebol is combined with Cortisone acetate.
DeflazacortThe risk or severity of edema formation can be increased when Clostebol is combined with Deflazacort.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Androstane steroids
Direct Parent
Androgens and derivatives
Alternative Parents
Halogenated steroids / 3-oxo delta-4-steroids / 17-hydroxysteroids / Delta-4-steroids / Cyclohexenones / Alpha-chloroketones / Secondary alcohols / Cyclic alcohols and derivatives / Vinyl chlorides / Chloroalkenes
show 3 more
Substituents
17-hydroxysteroid / 3-oxo-delta-4-steroid / 3-oxosteroid / 4-halo-steroid / Alcohol / Aliphatic homopolycyclic compound / Alpha-chloroketone / Alpha-haloketone / Androgen-skeleton / Carbonyl group
show 19 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
C19 steroids (androgens) and derivatives (LMST02020019)

Chemical Identifiers

UNII
Z7D4G976SH
CAS number
1093-58-9
InChI Key
KCZCIYZKSLLNNH-FBPKJDBXSA-N
InChI
InChI=1S/C19H27ClO2/c1-18-10-8-15(21)17(20)14(18)4-3-11-12-5-6-16(22)19(12,2)9-7-13(11)18/h11-13,16,22H,3-10H2,1-2H3/t11-,12-,13-,16-,18+,19-/m0/s1
IUPAC Name
(1S,2R,10R,11S,14S,15S)-6-chloro-14-hydroxy-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-5-one
SMILES
[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=C(Cl)C(=O)CC[C@]12C

References

General References
Not Available
KEGG Drug
D07731
PubChem Compound
68947
PubChem Substance
46505505
ChemSpider
62171
RxNav
61686
ChEBI
135372
ChEMBL
CHEMBL2106571
ZINC
ZINC000004025021
Wikipedia
Clostebol

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)189 °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility0.0153 mg/mLALOGPS
logP3.57ALOGPS
logP3.75ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)19.31ChemAxon
pKa (Strongest Basic)-0.88ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area37.3 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity89.22 m3·mol-1ChemAxon
Polarizability36.16 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9754
Caco-2 permeable+0.828
P-glycoprotein substrateSubstrate0.6367
P-glycoprotein inhibitor INon-inhibitor0.6429
P-glycoprotein inhibitor IINon-inhibitor0.9333
Renal organic cation transporterNon-inhibitor0.7453
CYP450 2C9 substrateNon-substrate0.8222
CYP450 2D6 substrateNon-substrate0.8968
CYP450 3A4 substrateSubstrate0.7867
CYP450 1A2 substrateNon-inhibitor0.8944
CYP450 2C9 inhibitorNon-inhibitor0.8654
CYP450 2D6 inhibitorNon-inhibitor0.8922
CYP450 2C19 inhibitorNon-inhibitor0.7617
CYP450 3A4 inhibitorNon-inhibitor0.8467
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8156
Ames testNon AMES toxic0.889
CarcinogenicityNon-carcinogens0.9243
BiodegradationNot ready biodegradable0.989
Rat acute toxicity1.7601 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8594
hERG inhibition (predictor II)Non-inhibitor0.6749
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on July 31, 2007 07:10 / Updated on June 12, 2020 10:51